Trial · NCT06551129
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
NCT06551129, Recruiting, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Real-world Patient Reported Outcomes Among Patients Treated With Camzyos. Trials, record NCT06551129. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06551129
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
- NCT number
- NCT06551129
- Status
- Recruiting
- Enrollment
- 118 participants, estimated
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Mavacamten
- First posted
- 2024-08-13
- Last updated
- 2024-11-07
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participant Hypertrophic Cardiomyopathy symptoms as assessed by Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ v2,0 - 7-day recall version) | Baseline and weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96 | |
| Primary | Participant physical limitation, symptom stability, symptom frequency, symptom burden, self-efficacy, QoL, and social limitations as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ-23) | Baseline and weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96 | |
| Primary | Participant mavacamten treatment status | Weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96 | |
| Primary | Other pharmacological and surgical treatments for obstructive hypertrophic cardiomyopathy (HCM) | Baseline and weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96 | |
| Primary | Participant symptom severity as assessed by self-assessed New York Heart Association (SA-NYHA) functional class | Baseline and weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96 | |
| Primary | Participant change in symptom severity as assessed by Patient Global Impression of Change (PGI-C) | Weeks 2, 4, 8, 12, 24, 30, 48, 72, and 96 | |
| Primary | Participant septal reduction therapy | Baseline and weeks 12, 30, 48 and 96 | |
| Primary | Participant major injury or surgery since previous survey | Weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96 | |
| Primary | Participant survey response on experience with CAMZYOS Risk Evaluation and Mitigation Strategy program (REMS) Program | Baseline and weeks 4, 12, 30, 48, 72 and 96 | |
| Primary | Participant medical history | Baseline |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06551129
GET https://conductscience.org/api/trials/v1/NCT06551129/registered